Okey Stephanie sold $246K of CRNX
Okey Stephanie sold 6,900 shares of Crinetics Pharmaceuticals, Inc. (CRNX) at an average of $35.67 ($35.62–$36.22, $0.25M total) across 2 trades on 2026-06-17 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The filing updates the insider ownership record but does not, by itself, change fundamentals or guidance. The most actionable takeaway is monitoring for any pattern of subsequent insider transactions.
Market read
Traders may briefly reassess sentiment around insider activity, but the 10b5-1 framing reduces the informational content.
What to watch
The article provides only the sale details; it does not state whether other insiders filed buys/sells around the same period or whether there were concurrent corporate events.
Background
This is an SEC Form 4 insider transaction: director Okey Stephanie sold shares in open-market transactions under a pre-arranged Rule 10b5-1 plan.
Ticker impact
SEC Form 4 shows director Okey Stephanie sold 6,900 shares of Crinetics Pharmaceuticals on 2026-06-17 under a 10b5-1 plan.
Low likelihood of a sustained price move solely from this filing; any reaction would be short-lived unless accompanied by other news.
The disclosure is an open-market sale by a director, explicitly tied to a pre-arranged 10b5-1 plan, with no accompanying operational/regulatory/financial catalyst in the text.
Market effects
No sector read-through provided; this is company-specific insider transaction disclosure only.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated or sizable insider sales can still coincide with internal expectations; traders may watch for follow-on filings or additional insider activity.
Key entities
- issuerCrinetics Pharmaceuticals, Inc.
Subject of the Form 4 insider sale disclosure (CRNX).
- insiderOkey Stephanie
Director who sold 6,900 shares on 2026-06-17 under a 10b5-1 plan.
